Next Phase Newsletter

A hybrid family office operating in the USA can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said, the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA can invest anywhere from $4-30M, with $11M being the median initial check size. The firm invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.

The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.

The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm headquartered in Canada with offices worldwide manages a variety of different investment vehicles including private equity and multi-strategy funds.  In the life sciences, the firm makes equity investments typically at Series A. The firm’s minimum investment is $2M and can go up to $20M.  The firm focuses on companies based in North America but has the capacity to invest worldwide.

In the life sciences, the firm focuses on medical devices, diagnostics and digital health companies.  The firm prefers to invest in companies that are close to commercialization or which are already generating revenue (for example, device companies must ideally be ready to file for a CE Mark, 510k or Health Canada application).

The firm prefers to invest in experienced entrepreneurs who have deep knowledge of their sector. The firm only invests in companies developing products that have a clear path to market, and which serve a clear need; the firm prefers to invest in companies that are no more than a year from obtaining revenues.  As the firm has offices globally, the firm is well placed to help portfolio companies make international distribution or license/royalty agreements.  The firm invests in both public and privately-held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the USA had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a $300 million strategic corporate venture capital fund by a Japanese pharma. The fund seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications. While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the parent company’s established expertise in the field of oncology product discovery and development, The firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a hybrid family office and operating company based on the East Coast. The firm can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a healthcare-focused venture capital firm that was founded in 1982. Its offices are located in the Midwest. The firm has over $200 million in assets under management and is currently investing out of its sixth fund. The firm makes seed and early-stage investments in healthcare companies, with typical initial investment sizes ranging from $250k to $3.5 million, and total investment up to $8 million over the life cycle of a company. Venture Investors is a regional fund and focused on investments in the Midwest.

The firm focuses on early-stage investments in biopharma, medtech, tools/dx and digital health sectors. The firm is interested in platform technologies that can improve patient outcomes while lowering the cost of care.

The firm looks for experienced management teams with previous start-up experience, industry knowledge, and proven track records as well as scientific founders who are committed to building world class management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.